News New NICE rules could deny drugs to rare disease patients Patients could be denied treatments, says BIA
News NICE recommends Novartis kidney cancer drug Afinitor finally recommended after rejection in 2011.
Views & Analysis Budget impact and cost effectiveness: Can the UK learn from ... Leela Barham examines the approach of the Institute for Clinical and Economic Review.
News £80m fund speeds up access to NICE-approved drugs in Wales Patients in Wales are to gain faster access to medicines recommended by NICE and Wales’ own cost-effectiveness body, the All Wales Medicines Strategy Group (AWMSG).
Views & Analysis The budget impact of new medicines What could be the impact of proposed new ‘budget impact threshold’ for drugs?
News Amicus set for share of Fabry market after NICE approval England and Wales’ cost effectiveness watchdog NICE has given a final recommendation to a new treatment for the rare Fabry disease.
Oncology On the benefits of earlier oncological intervention, with Jo... As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
